Abstract
Treatment with rhGH has direct anabolic effects in catabolic adult intensive care patients. Preceding a randomised double blind placebo controlled investigation, a pilot study was performed in 10 type II (non-symmetric) IUGR preterm infants (birthw. 920 ± 155 g., gest. age 30 ± 2 wks.) (SDS≤-2) regarding possible early postnatal anabolic effects of rhGH on protein metabolism. 5 infants received a daily subcutaneous injection with 0.5 (n = 2) or 1.0 (n=3) IU.kg−d− rhGH and 5 IUGR infants were studied as controls. Daily rhGH was started one week after birth and stopped 6-8 weeks later. At postnatal age 41 ± 15 d. protein metabolism was studied during indirect calorimetry using 1-13C-leucine turnover studies. All infants received continuous special formula feeding via a nasogastric drip {120 kcal.kg−1d−1). Results of protein intake, turnover, synthesis, breakdown, and accretion in g.kg−1,d−1 as means ± S.D. (sign, of diff. tested by Mann-Whitney U test):
Conclusions: These results indicate a stimulatory effect of rhGH in IUGR preterm infants on protein turnover, synthesis and breakdown not resulting, however, in a significant rise of net-protein accretion. Additional studies are necessary to give conclusive evidence of a non-anabolic or possibly even catabolic effect of daily rhGH treatment in these infants.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Tolerio-Eppinga, L., Kulik, W., Jakobs, C. et al. 231 EFFECTS OF EARLY POSTNATAL RECOMBINANT HUMAN GROWTH HORMONE (rhGH) TREATMENT ON PROTEIN METABOLISM IN INTRA UTERINE GROWTH RETARDED (IUGR) PRETERM INFANTS: a pilot study. Pediatr Res 36, 41 (1994). https://doi.org/10.1203/00006450-199407000-00231
Issue date:
DOI: https://doi.org/10.1203/00006450-199407000-00231
